A Study of Mitoxantrone Hydrochloride Liposome Injection in Advanced Recurrent or Metastatic Breast Cancer
A Randomized, Open-label, Positive-controlled, Single-institutional, Phase Ⅱ of Mitoxantrone Hydrochloride Liposome Injection in Advanced Recurrent or Metastatic Breast Cancer
Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Listed as NCT02596373, this PHASE2 trial focuses on Advanced Recurrent or Metastatic Breast Cancer and remains ongoing. Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., it has been updated 7 times since 2015, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Sep 2018 — Sep 2020 [monthly]
Recruiting PHASE2
Status: Unknown Status → Recruiting
▶ Show 2 earlier versions
-
Feb 2018 — Sep 2018 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2017 — Feb 2018 [monthly]
Recruiting PHASE2
First recorded
Jun 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .